HCC: Treatment-Related Adverse Events, Case Discussions and Q&A – Episode 2

In this second episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss how to identify, prevent and mitigate treatment-related adverse events, and review cases with careful considerations for patient-specific factors guiding treatment selection, followed by a question-and-answer session on the management of patients with HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Amit Singal, MD, MS

Mark Yarchoan, MD

Bridget O’Brien, DNP, FNP-BC, AOCNP

Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.

Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.

Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.